Loading…
Loading…
Nika Pharmaceuticals, Inc. (OTCQB: NIKA) updates its shareholders regarding ongoing negotiations for up to 50 million USD and expected funding timeline.
HENDERSON, Nev., June 04, 2026 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA) is currently engaged in active discussions with several investors from Europe and the US who have demonstrated significant interest in NIKA; negotiations with two of these parties are in advanced stages.
HENDERSON, Nev., March 06, 2026 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA) announces that it has signed a consultancy agreement with MD Global Partners LLC, a leading Manhattan-based investment bank.
HENDERSON, Nev., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA) appeared on The Street Reports podcast where CEO Dimitar Savov shared the progress the company has made thus far and outlined what is expected for 2026, which will be a crucial year for the company.
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com
Nika Pharmaceuticals, Inc. (OTCQB: NIKA) projects €8.5 Billion revenue from its distribution agreements for Nigeria, Ukraine, UAE, Iraq, Syria, and Jordan.
Nika Pharmaceuticals, Inc. (OTCQB: NIKA)'s report on the therapeutic effect of ITV-1 on AIDS, Cancer, Hepatitis volunteers and Nika Europe factory progress